Precision Medicine in Diabetes Initiative
The convergence of advances in medical science, human biology, data science, and technology has enabled a generation of new insights into the phenotypes underlying the diagnosis of diabetes. Deeper knowledge of these conditions has emerged from populations around the world, illuminating the differences in how diabetes presents, its variable prevalence, and how best practice in treatment varies across populations. In precision medicine, diagnostic tests help optimize a patient’s treatment strategies. Precision medicine proposes custom delivery of health care, with medical practices, testing, decisions, and treatments tailored to the individual patient level, basically, identifying the right treatment, for each patient, at the right time.
ADA has partnered with the European Association for the Study of Diabetes (EASD) on the Precision Medicine in Diabetes Initiative (PMDI) and our work in precision medicine’s innovative and pioneering technology is providing the foundation for great strides in advancements in diabetes care.
|
The Precision Medicine in Diabetes Initiative – Vision and Future Direction The following, presented at the 2021 Precision Diabetes Medicine (PDM2021) Virtual Symposium in June by Paul W. Franks, PhD, Task Force Co-Chair, provides valuable insight into the important work of the PMDI to advance precision medicine in diabetes and the overall translational impact to patient care and outcomes.
|
|---|
|
ADA recently hosted Precision Medicine in Diabetes - 2021 Scientific Sessions Post Game Day Commentary. This event features a panel format with lively conversation from four experts in the diabetes scientific field, reflecting on highlights of precision medicine focused presentations from ADA’s Scientific Sessions, examining different points, identifying potential areas not covered or important gaps in knowledge and, sharing additional information pertinent to precision medicine that may not have been covered. Moderator
Panelists
|
|
|
Links to 2021 ADA Scientific Sessions Presentations |
|
|
Pharmacogenetics and the Basis of Drug Responses in Diabetes, Ewan Pearson, PhD |
|
|
Leveraging Genetics for Drug Target Identification - Jose Florez, MD, PhD |
|
|
Debate - Precision Nutrition - Are We There Yet |
|
|
Putting it all together – Precision Medicine gets Precise, Jonathan Himmelfarb, MD |
|
PMDI Outcomes
- Support research and career development initiatives focused on precision diabetes medicine.
- Enhance use of data (e.g. -omics assays, electronic health records, patient registries, digital imaging technologies and/or wearable devices) that address contexts of use relevant to diabetes.
- Recommend guidelines for clinical implementation of precision diabetes medicine.
- Educate health care providers.
- Promote public engagement/awareness of precision diabetes medicine.
PMDI Objectives
The overall objective of the initiative is to improve diabetes care by realizing the promise of precision medicine for diabetes. To achieve this objective, several short-, medium- and long-term objectives have been identified.
- Improve diabetes diagnostics.
- Establish what evidence we have and what evidence is needed to develop best practice guidelines and best practice study design.
- Provide education to implement best practice guidelines and best practice research.
- Establish a research program to address open questions.
- Accelerate the process for getting access to trials and for regulatory authorization.
- Modify guidelines to incorporate new recommendations in precision medicine.
PMDI Approach
Our approach is stepwise, incorporating and building the evidence base for precision medicine in diabetes that achieves quantifiable, implementable, probabilistic outcomes based on etiology and risk scores. The initiative will rely on expertise and collaboration from many stakeholders garnered through a hub-and-spoke model of working groups reporting to a steering committee with the overall initiative managed by an executive oversight committee.
- Louis H. Philipson, MD, PhD, University of Chicago, American Diabetes Association
- John Nolan, MD, European Association for the Study of Diabetes
- Paul W. Franks, PhD, Lund University, Task Force Co-Chair
- Stephen S. Rich, PhD, University of Virginia, Task Force Co-Chair
- Paul W. Franks, PhD, Lund University, Task Force Co-Chair
- Stephen S. Rich, PhD, University of Virginia, Task Force Co-Chair
- Wendy Chung, MD, PhD, Columbia University
- Jessica Dunne, PhD, JDRF
- Jose C. Florez, MD, PhD, Massachusetts General Hospital, Harvard Medical School
- Andrew Hattersley, FRCP, University of Exeter
- Christine G. Lee, MD, MS, National Institute of Diabetes and Digestive and Kidney Diseases
- Mark McCarthy, FRCP, PhD, University of Oxford
- John Nolan, MD, Trinity College Dublin, European Association for the Study of Diabetes
- Jill Norris, MPH, PhD, University of Colorado, Denver
- Ewan Pearson, FRCP, PhD, University of Dundee
Advisors:
- Frank Hu, MD, PhD, Harvard Medical School
- Gail Jarvik, MD, PhD, University of Washington
Collaborating Organizations
Join Us
Please click here if you’re interested in receiving communications about the Precision Medicine in Diabetes initiative.